Search
Smith & Nephew PLC
SNNAdd to Watchlist
30.290USD
+0.250+0.83%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
12.81BMarket Cap
26.95P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.83%
5 Days
+3.06%
1 Month
+2.02%
6 Months
-8.60%
Year to Date
-7.68%
1 Year
+0.23%
Key Figures
30.380Open
30.470High
1.05MVolume
26.95P/E TTM
12.38P/E Dynamic
0.752Dividend TTM
0.25%Turnover Ratio
30.040Prev. Close
30.205Low
16.76MTurnover
31.24P/E Static
2.43P/B
2.48%Div Yield TTM
4.62%ROA
38.79052wk High
0.79Volume Ratio
412.00MNet Profit
424.86MShares
1.1239EPS TTM
0.59Beta
9.14%ROE
28.40052wk Low
0.88%Amplitude
70.62%Gross Margin
12.81BMarket Cap
1.21Reward/Risk
0.97%Risk Rate
TradingKey Stock Score of Smith & Nephew PLC
Currency: USD Updated: 2026-06-29Key Insights
Smith & Nephew PLC's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered undervalued, ranking 85 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 35.28.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Smith & Nephew PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Smith & Nephew PLC Highlights
StrengthsRisks
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 6.16B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 79.37%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 79.37%.
Undervalued
The company’s latest PE is 26.94, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 30.95M shares, decreasing 27.07% quarter-over-quarter.
Held by Sarah Ketterer
Star Investor Sarah Ketterer holds 10.59M shares of this stock.
Analyst Rating
Based on
5
analysts
Hold
Current Rating
35.278
Target Price
+17.44%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Smith & Nephew PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Smith & Nephew PLC Info
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
Ticker SymbolSNN
CompanySmith & Nephew PLC
CEONath (Deepak S)
Websitehttps://www.smith-nephew.com/
Related Instruments
-1.97%
-1.34%
-1.50%
+0.31%
-1.73%
-0.74%
-0.71%
-0.09%
+0.08%
-1.83%
-1.45%
-1.76%
-1.57%
+0.44%
+1.90%
+1.33%
-0.49%
-2.82%
+3.97%
-2.31%Popular Instruments
52225.500
+72.300 (+0.14%)
29835.900
+128.200 (+0.43%)
7447.000
+14.800 (+0.20%)
15554.000
+103.000 (+0.67%)
70069.000
-405.000 (-0.57%)
6277.600
+21.800 (+0.35%)
70.441
+0.125 (+0.18%)
281.740
-2.040 (-0.72%)
194.970
+2.440 (+1.27%)
4025.410
+9.820 (+0.24%)
FAQs
What is the current price of Smith & Nephew PLC (SNN)?
The current price of Smith & Nephew PLC (SNN) is 30.29.
What is the symbol of Smith & Nephew PLC?
The ticker symbol of Smith & Nephew PLC is SNN.
What is the 52-week high of Smith & Nephew PLC?
The 52-week high of Smith & Nephew PLC is 38.79.
What is the 52-week low of Smith & Nephew PLC?
The 52-week low of Smith & Nephew PLC is 28.40.
What is the market capitalization of Smith & Nephew PLC?
The market capitalization of Smith & Nephew PLC is 12.87B.
Is Smith & Nephew PLC (SNN) currently rated as Buy, Hold, or Sell?
According to analysts, Smith & Nephew PLC (SNN) has an overall rating of signal_hold, with a price target of 35.28.
What is the Earnings Per Share (EPS TTM) of Smith & Nephew PLC (SNN)?
The Earnings Per Share (EPS TTM) of Smith & Nephew PLC (SNN) is 1.44.
